AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia

Aneel Paulus, Kasyapa Chitta, Sharoon Akhtar, David Personett, Kena C. Miller, Kevin J. Thompson, Jennifer Carr, Shaji Kumar, Vivek Roy, Stephen M. Ansell, Joseph R. Mikhael, Angela Dispenzieri, Craig B. Reeder, Candido E. Rivera, James Foran, Asher Chanan-Khan

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia'. Together they form a unique fingerprint.

Medicine & Life Sciences